SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-18-031096
Filing Date
2018-05-08
Accepted
2018-05-08 08:01:30
Documents
52
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q a18-8686_110q.htm 10-Q 943939
2 EX-10.2 a18-8686_1ex10d2.htm EX-10.2 605130
3 EX-31.1 a18-8686_1ex31d1.htm EX-31.1 13118
4 EX-31.2 a18-8686_1ex31d2.htm EX-31.2 13095
5 EX-32.1 a18-8686_1ex32d1.htm EX-32.1 6278
6 EX-32.2 a18-8686_1ex32d2.htm EX-32.2 6932
13 GRAPHIC g86861ks15i001.jpg GRAPHIC 9537
14 GRAPHIC g86861ks15i002.jpg GRAPHIC 6991
  Complete submission text file 0001104659-18-031096.txt   4123470

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT nbrv-20180331.xml EX-101.INS 563279
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nbrv-20180331.xsd EX-101.SCH 30539
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nbrv-20180331_cal.xml EX-101.CAL 37494
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nbrv-20180331_def.xml EX-101.DEF 131324
11 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT nbrv-20180331_lab.xml EX-101.LAB 308702
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nbrv-20180331_pre.xml EX-101.PRE 233389
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 18813009
SIC: 2834 Pharmaceutical Preparations